Emmy Foster
Family · Las Vegas, NVNPI 1841845278
Payments from drug & device makers
Across 200 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$516
- Neurocrine Biosciences, Inc.$345
- Amgen$251
- Lundbeck LLC$172
- Genentech USA, Inc.$127
- plus $948 from 22 others
What the payments were for
- Food & beverage$3,617100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $1,258 |
| Novartis | 42 | $516 |
| Neurocrine Biosciences, Inc. | 14 | $345 |
| Amgen | 16 | $251 |
| Lundbeck LLC | 5 | $172 |
| Genentech USA, Inc. | 6 | $127 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $120 |
| AstraZeneca | 5 | $95 |
| Pfizer | 4 | $72 |
| SK Life Science, Inc. | 4 | $70 |
| UCB, Inc. | 4 | $68 |
| ANI Pharmaceuticals, Inc. | 3 | $63 |
| Sunovion Pharmaceuticals Inc. | 5 | $55 |
| Octapharma USA, Inc. | 3 | $41 |
| Biogen | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Ipsen Biopharmaceuticals, Inc | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 2 | $38 |
| Argenx US, Inc. | 2 | $31 |
| Sumitomo Pharma America, Inc. | 2 | $28 |
| Sanofi | 1 | $26 |
| Philips North America LLC | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Tanabe Pharma America, Inc. | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| GRT US Holding, Inc. | 1 | $18 |
| Medtronic | 1 | $15 |
| Impel Pharmaceuticals Inc. | 1 | $14 |
How this compares
$3,617 in reported general payments places this provider in the 90th percentile of 1,501 family providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 33 | $42,337 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $14,853 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,952 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $1,021 |
| Divalproex Sodium | 13 | $869 |
| Atorvastatin Calcium | 84 | $863 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 35 | $676 |
| Potassium Chloride | 38 | $601 |
| Ondansetron OdtOndansetron | 22 | $560 |
| Tamsulosin Hcl | 30 | $548 |
| Amlodipine Besylate | 83 | $523 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 15 | $492 |
| Bupropion Hcl | 12 | $489 |
| Gabapentin | 40 | $453 |
| Levothyroxine Sodium | 46 | $432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $72 | $42,33733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,501 family providers in Nevada.
Other family in Las Vegas
- John PhoenixLas Vegas$281K
- Hollie TylerLas Vegas$118K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
- Kelly PapeshLas Vegas$44K
- Erin WilkinsonLas Vegas$43K
- Anna Melisa Lopez-SanglayLas Vegas$42K
- Bernard BlanksLas Vegas$26K
- Hillary DursteinLas Vegas$21K
- Victoria HughesLas Vegas$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.